



StemCell United Limited

ASX: SCU

A Singapore based Biotechnology Company

Corporate Structure:

Shares on issue: 363 M

Directors:

Dr. Gu Huan Qing
Founder & Executive Director

Ms Jamie Khoo
Non-Executive Chairman

Mr Chow-Yee Koh
Non-Executive Director & Company Secretary

Registered Office:
Level 2, 350 Kent St.
Sydney NSW 2000 Australia

Singapore Office:
6 Defu Lane 2
Singapore 539466

Phone:
+61 2 9299 2289

Fax:
+61 2 9299 2239

Website:
www.scu.com.sg

StemCell United secures Strategic Cooperation Agreement with Guangzhou University of Chinese Medicine

- Strategic partnership with prestigious Chinese university positions SCU in large and lucrative TCM market
- Key milestone towards fast tracking further development and commercialisation of Company's two core products
- Collaboration will also focus on wider commercial applications for plant extracts – potential to unlock significant value
- SCU assessing further partnerships and joint ventures to accelerate growth and development, diversify revenue streams

9 December 2015, Sydney and Singapore: StemCell United Limited (ASX: SCU) ("SCU" or "the Company") is pleased to announce that the Company has recently executed a Strategic Cooperation Agreement with the Dongguan Academy of Chinese Medicine, a division of the prestigious Guangzhou University of Chinese Medicine (GUCM) in China.

Established in 1956, GUCM is one of the oldest and most respected universities of its kind in China, and was one of the first higher learning institutions given the right to confer Master's and doctoral degrees. GUCM has a rich history of teaching and research, with a faculty of approximately 500 professors and 700 lecturers, 13 established research institutions and affiliations with six hospitals.

Under the terms of its agreement with GUCM, SCU will work closely with the Academy, sharing technical knowledge, resources and research towards further development and commercialisation of Singapore based SCU's proprietary stem cell method to culture and grow plant extracts for use in Traditional Chinese Medicine (TCM).

Research will focus on the further development and commercialisation of the Company's unique stem cell extraction process for the highly valued orchid extract *Denobrium Officinale et Migo* (or 'Denobrium'), which is sought after in TCM and commonly sells for between US\$1,000 to US\$3,000 per kilo.

The collaboration will also examine the further development and wider applications in TCM for the *Daemonorops Draco Blume* extract (commonly known as 'Resina' or 'Dragon's Blood') that SCU currently sells to pharmaceutical companies in Asia for circa US\$350 per kilo.



SCU is greatly encouraged by this partnership with GUCM, a leader in the field of research in TCM in China and globally, as it represents an important milestone for the Company towards the broader commercialisation of its two core products.

Commenting on the Strategic Cooperation Agreement with GUCM, SCU's CEO and Executive Director, Mr Huan Qing (Phillip) Gu stated: "This partnership with Guangzhou University of Chinese Medicine is a great honour for SCU, as our alliance with this highly regarded institution is a mark of trust and credibility in the Company and our proprietary technology. This will also assist SCU to gain greater awareness and visibility in the vast TCM market in China."

"This collaboration will also enable us to fast track the development and broader commercialisation of our two core products, for which we see much untapped potential across a number of expanding sectors. This will enable us to further grow and diversify our existing revenue streams, while unlocking significant value for shareholders."

"We are also currently assessing additional partnerships and joint ventures through which we might accelerate the execution of our business strategy, and I look forward to updating shareholders on these initiatives in the near future."

SCU is also pleased to advise shareholders and other interested parties that it has launched a Company Twitter account as an additional platform through which it will distribute ASX/media releases, along with other useful news and information on the TCM sector, on a regular basis. To follow SCU on Twitter, please refer to the link below.

– Ends –

<p><u>For Further Information please contact:</u></p> <p>Ben Jarvis, Six Degrees Investor Relations Ph: +61 413 150 448</p>	<p>About StemCell United:</p> <p>StemCell United Limited (ASX:SCU), is a Singapore based biotechnology company with a focus on using proprietary stem cell technology to culture and grow plant extracts for use in Traditional Chinese Medicine (TCM). The Company recently relisted on the ASX following a successful capital raising and aims to expand sales of Resina to TCM manufacturers and wholesalers worldwide, while commercialising its proprietary stem cell extraction technology.</p>
---	--



www.twitter.com/StemCellUnited